Ongoing investments in its Fishers, Indiana and Latina, Italy sites are expanding capacity for high-value products, while the company pivots away from other categories.
The company launched two cGMP facilities in Irvine, California, supporting formulation development, clinical manufacturing, and commercial production of tablets and capsules.
The system is designed to support commercial production of amorphous solid dispersions used to improve the bioavailability of poorly soluble drug candidates.
